Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Meritxell Bellet; Faten Ahmad; Rafael Villanueva; Carolina Valdivia; Julián Palomino-Doza; Ada Ruiz; Xavier Gonzàlez; Encarna Adrover; Analía Azaro; Maria Valls-Margarit; Josep Lluís Parra; Juan Aguilar; Maria Vidal; Anastasi Martín; Joaquín Gavilá; Santiago Escrivá-de-Romaní; Antonia Perelló; Cristina Hernando; Ainhara Lahuerta; Pilar Zamora; Victoria Reyes; María Alcalde; Helena Masanas; Pamela Céliz; Isabel Ruíz; Miguel Gil; Miguel Àngel Seguí; Lorena de la Peña

doi:10.1177/1758835919833867

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Meritxell Bellet^*, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Ada Ruiz, Xavier Gonzàlez, Encarna Adrover, Analía Azaro, Maria Valls-Margarit, Josep Lluís Parra, Juan Aguilar, Maria Vidal, Anastasi Martín, Joaquín Gavilá, Santiago Escrivá-de-Romaní, Antonia Perelló, Cristina Hernando, Ainhara Lahuerta, Pilar ZamoraVictoria Reyes, María Alcalde, Helena Masanas, Pamela Céliz, Isabel Ruíz, Miguel Gil, Miguel Àngel Seguí, Lorena de la Peña

^*Autor correspondiente de este trabajo

Departamento de Medicina

Producción científica: Contribución a una revista › Artículo de revisión › Investigación › revisión exhaustiva

42 Citas (Scopus)

Resumen

Drug–drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the ‘First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications’. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.

Idioma original	Inglés
Publicación	Therapeutic Advances in Medical Oncology
Volumen	11
DOI	https://doi.org/10.1177/1758835919833867
Estado	Publicada - 1 may 2019

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1177/1758835919833867

Otros archivos y enlaces

Enlace a la publicación en Scopus

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Bellet, M. (Colaborador), Ahmad, F. (Creador), Villanueva, R. (Creador), Valdivia, C. (Creador), Palomino-Doza, J. (Creador), Ruiz, A. (Creador), Gonzàlez, X. (Creador), Adrover, E. (Creador), Azaro, A. (Creador), Valls-Margarit, M. (Creador), Parra, J. L. (Creador), Aguilar, J. (Creador), Vidal, M. (Creador), Martín, A. (Colaborador), Gavilá, J. (Creador), Escrivá-de-Romaní, S. (Colaborador), Perelló, A. (Creador), Hernando, C. (Creador), Lahuerta, A. (Colaborador), Zamora, P. (Creador), Reyes, V. (Creador), Alcalde, M. (Creador), Masanas, H. (Creador), Céliz, P. (Creador), Ruíz, I. (Creador), Gil, M. (Creador), Seguí, M. À. (Creador) & de la Peña, L. (Colaborador), figshare, 10 may 2019
DOI: 10.25384/sage.c.4517534.v1, https://sage.figshare.com/collections/Palbociclib_and_ribociclib_in_breast_cancer_consensus_workshop_on_the_management_of_concomitant_medication/4517534/1
Dataset: Conjunto de datos

Citar esto

Bellet, M., Ahmad, F., Villanueva, R., Valdivia, C., Palomino-Doza, J., Ruiz, A., Gonzàlez, X., Adrover, E., Azaro, A., Valls-Margarit, M., Parra, J. L., Aguilar, J., Vidal, M., Martín, A., Gavilá, J., Escrivá-de-Romaní, S., Perelló, A., Hernando, C., Lahuerta, A., ... de la Peña, L. (2019). Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Therapeutic Advances in Medical Oncology, 11. https://doi.org/10.1177/1758835919833867

@article{82f69244cc624c479de04be730bbe08d,

title = "Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication",

abstract = "Drug–drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the {\textquoteleft}First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications{\textquoteright}. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.",

keywords = "breast cancer, CDK inhibitors, palbociclib, ribociclib",

author = "Meritxell Bellet and Faten Ahmad and Rafael Villanueva and Carolina Valdivia and Juli{\'a}n Palomino-Doza and Ada Ruiz and Xavier Gonz{\`a}lez and Encarna Adrover and Anal{\'i}a Azaro and Maria Valls-Margarit and Parra, {Josep Llu{\'i}s} and Juan Aguilar and Maria Vidal and Anastasi Mart{\'i}n and Joaqu{\'i}n Gavil{\'a} and Santiago Escriv{\'a}-de-Roman{\'i} and Antonia Perell{\'o} and Cristina Hernando and Ainhara Lahuerta and Pilar Zamora and Victoria Reyes and Mar{\'i}a Alcalde and Helena Masanas and Pamela C{\'e}liz and Isabel Ru{\'i}z and Miguel Gil and Segu{\'i}, {Miguel {\`A}ngel} and {de la Pe{\~n}a}, Lorena",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2019.",

year = "2019",

month = may,

day = "1",

doi = "10.1177/1758835919833867",

language = "English",

volume = "11",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

Bellet, M, Ahmad, F, Villanueva, R, Valdivia, C, Palomino-Doza, J, Ruiz, A, Gonzàlez, X, Adrover, E, Azaro, A, Valls-Margarit, M, Parra, JL, Aguilar, J, Vidal, M, Martín, A, Gavilá, J, Escrivá-de-Romaní, S, Perelló, A, Hernando, C, Lahuerta, A, Zamora, P, Reyes, V, Alcalde, M, Masanas, H, Céliz, P, Ruíz, I, Gil, M, Seguí, MÀ & de la Peña, L 2019, 'Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication', Therapeutic Advances in Medical Oncology, vol. 11. https://doi.org/10.1177/1758835919833867

TY - JOUR

T1 - Palbociclib and ribociclib in breast cancer

T2 - consensus workshop on the management of concomitant medication

AU - Bellet, Meritxell

AU - Ahmad, Faten

AU - Villanueva, Rafael

AU - Valdivia, Carolina

AU - Palomino-Doza, Julián

AU - Ruiz, Ada

AU - Gonzàlez, Xavier

AU - Adrover, Encarna

AU - Azaro, Analía

AU - Valls-Margarit, Maria

AU - Parra, Josep Lluís

AU - Aguilar, Juan

AU - Vidal, Maria

AU - Martín, Anastasi

AU - Gavilá, Joaquín

AU - Escrivá-de-Romaní, Santiago

AU - Perelló, Antonia

AU - Hernando, Cristina

AU - Lahuerta, Ainhara

AU - Zamora, Pilar

AU - Reyes, Victoria

AU - Alcalde, María

AU - Masanas, Helena

AU - Céliz, Pamela

AU - Ruíz, Isabel

AU - Gil, Miguel

AU - Seguí, Miguel Àngel

AU - de la Peña, Lorena

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Drug–drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the ‘First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications’. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.

AB - Drug–drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the ‘First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications’. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.

KW - breast cancer

KW - CDK inhibitors

KW - palbociclib

KW - ribociclib

UR - http://www.scopus.com/inward/record.url?scp=85066835008&partnerID=8YFLogxK

U2 - 10.1177/1758835919833867

DO - 10.1177/1758835919833867

M3 - Review article

AN - SCOPUS:85066835008

SN - 1758-8340

VL - 11

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

ER -

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Conjuntos de datos

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Citar esto